



Fresenius Medical Care

The World's Leading Renal Therapy Company

**Jefferies 2010 Global Specialty Pharma & European Healthcare
Conference**

London, October 6, 2010



Fresenius Medical Care




Forward-looking Statements

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

1. Business Update & Outlook 2010

2. Growth Strategy and Summary





First Half 2010 – Profit & Loss

US\$ millions	H1 2009	H1 2010	Growth
Net revenue	5,323	5,828	9%*
Operating income (EBIT)	813	888	9%
EBIT margin in %	15.3	15.2	
Interest expense, net	149	135	
Income before income tax	664	753	13%
Income tax expense	214	257	
Tax rate	32%	34%	
Non-controlling interest	31	37	
Net income attributable to FMC AG & Co. KGaA	419	459	10%

* 8% growth at constant currency, 7% organic growth




First Half 2010 – Revenue

Total revenue increased 9% to \$5,828 m

North America	
Revenue	\$3,986 m
Growth actual	9%
Growth organic	8%

International	
Revenue	1,842 m
Growth cc	6%
Growth organic	4%



Latin America	
Revenue	\$281m
Growth	20% / 9% cc

Europe	
Revenue	\$1,224 m
Growth	7% / 5% cc

Asia-Pacific	
Revenue	\$337 m
Growth	16% / 7% cc

cc = constant currency

First Half 2010 – Dialysis Services Global

Very strong revenue growth globally

US\$ millions	H1 2009	H1 2010	Growth	cc
North America	3,254	3,578	10%	
International	723	817	13%	9%
Total	3,977	4,395	11%	10%

- Good organic treatment growth of 4.3% globally
- Continued strong revenue per treatment development

cc = constant currency

First Half 2010 – Dialysis Products

Good product growth in H1 2010


US\$ millions	H1 2009	H1 2010	Growth	cc
Total revenue <small>(incl. internal revenue)</small>	1,813	1,962	8%	6%
External revenue	1,346	1,433	6%	4%
North America	396	408	3%	
International	950	1,025	8%	4%

cc = constant currency



Days Sales Outstanding (DSO)

Continued excellent cash collection



First Half 2010 – Cash Flow

Operating cash flow at 11% of revenue

US\$ millions	H1 2009	H1 2010	Growth
Operating cash flow ¹⁾	437	643 11% of revenue	47%
Capital expenditures, net ¹⁾	(249)	(218)	
Free cash flow	188	425 7% of revenue	127%
Acquisitions, net of divestitures ^{1) 2)}	(81)	(150)	
Free cash flow, after acquisitions ^{1) 2)}	107	275	

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009

Expanded Dialysis Services and Products in Key Regions



- ▶ Acquired Asia Renal Care
 - ▶ Adding more than 100 clinics treating about 6,200 patients
 - ▶ Adding approximately \$80 million in annual revenue
- ▶ Expanded dialysis products business in Korea
 - ▶ Adding approximately \$15 million in annual revenue
 - ▶ Accretive to earnings in the first year
- ▶ Entered into long-term distributor agreement in Japan



- ▶ Expanded dialysis services business in Russia
 - ▶ Adding approximately \$25 million in annual revenue
 - ▶ Accretive to earnings in the first year

2010 – Outlook Reiterated



Fully on track for 2010 Targets

US\$ millions

Net revenue

Net income

attributable to FMC AG & Co. KGaA

Leverage ratio

(Debt/EBITDA)

Capital expenditures

Acquisitions

GUIDANCE

> \$12,000

\$950 - 980

< 2.5

~ \$550 - 650

up to \$500

1. Business Update & Outlook 2010


2. Growth Strategy and Summary



Development of Dialysis Patient Population




Fresenius Medical Care



- Renal failure persists worldwide
- Dialysis is the primary treatment modality on a global scale
- The number of global dialysis patients is expected to double by 2020



Market Opportunity by Region





Integrated Care

Therapy

Renal
Drugs



Patient Care

Products



4008S



2008K



5008S



SleepSafe



Liberty Cyclor



Components of Growth Strategy

Product

Services

Renal Pharma / Therapy

- Combine membrane, drug delivery and laboratory technology with proven dialysis drugs to provide superior outcomes

Integrated Care Looking Ahead to ACO



Global Strategy – Adapted Locally

ESRD Clinical Treatment Goals Are Similar on a Global Basis,

However:

FME's overall growth strategy must be implemented on a regional basis due to varying reimbursement and health care systems

FME's Products and Services by Region




Fresenius Medical Care



Industry's only Vertically Integrated Provider




Fresenius Medical Care






World Leader in Dialysis Services

North America




EMEA




We Lead in Every Major Market, Treating More Than 212,756 Patients Worldwide

Latin America



Asia Pacific



Based on company statements as of 6-30-2010 and estimates


* patients including managed clinics

Market Position by Major Product Groups



	<u>Rank 1</u>	<u>Rank 2</u>	<u>Rank 3</u>
Dialyzers	FME	Gambro	Nipro
Dialysis machines	FME	Gambro	Nikkiso
Hemodialysis concentrates	FME	Fuso	Gambro
Bloodlines	FME	Gambro	Kawasumi
Peritoneal dialysis products	Baxter	FME	Pisa

Dialyzers



Dialysis machines



Produced more than ~85,000,000 Dialyzers in 2009



Sorbent Products



2008 Sorbent System

Features

- 6 – 12 L tap water
- No water treatment
- Standard electrical hookup
- Conventional 3x per week
- Every other day dialysis therapy



Portable Artificial Kidney (PAK)

Device not Approved in the US

Features

- Compact
- Disposable circuits



Growth Strategy Implementation


23 Countries Account for > 92% of Revenue


	Services	Products
North America		
Canada	✓	✓
Mexico	✓	✓
USA	✓	✓
EMEA		
Czech Republic	✓	✓
France	✓	✓
Germany	✓	✓
Italy	✓	✓
Portugal	✓	✓
Spain	✓	✓
United Kingdom	✓	✓
Turkey	✓	✓
Poland	✓	✓
Russia	✓	✓
Romania	✓	✓
Asia Pacific		
Australia	✓	✓
China	✓	✓
Hong Kong	✓	✓
Japan	✓	✓
Korea	✓	✓
Taiwan	✓	✓
Latin America		
Argentina	✓	✓
Brazil	✓	✓
Colombia	✓	✓


Global Strategy - Services – Areas to Improve Dialysis Outcomes



Fresenius Medical Care








Global Strategy – Renal Pharma/Therapy – Bone Mineral Management



Fresenius Medical Care





Leadership

- **Maintain our global leadership position**
- **Continue to shape the future of the dialysis industry**

Quality

- **Maintain superior quality in products and services**

Growth

- **Benefit from product innovations**
- **Take opportunity of international growth potential**
- **Introduce new therapy offerings**
- **Continue horizontal expansion of service and product range**

Financial

- **Control cost and spending**
- **Seek attractive investment opportunities**
- **Continue profitable growth momentum**



**Thank you for your interest in
Fresenius Medical Care !**





Fresenius Medical Care

The World's Leading Renal Therapy Company

**Jefferies 2010 Global Specialty Pharma & European Healthcare
Conference**

London, October 6, 2010



Fresenius Medical Care



Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

Debt	Q2 2010	FY 2009	FY 2008	FY 2007
Short-term borrowings (incl. A/R program)	410	316	684	217
+ Short-term borrowings from related parties	9	10	1	2
+ Current portion of long-term debt and capital lease obligations	1,866	158	455	85
+ Current portion of trust preferred securities				670
+ Long-term debt and capital lease obligations, less current portion	2,949	4,428	3,957	4,004
+ Trust preferred securities	593	656	641	664
= Total debt	5,827	5,568	5,738	5,642

EBITDA	Q2 2010	FY 2009	¹⁾ FY 2008	FY 2007
Last twelve months operating income (EBIT)	1,830	1,756	1,672	1,580
+ Last twelve months depreciation and amortization	487	457	416	363
+ Non-cash charges	49	50	44	41
= EBITDA (annualized)	2,366	2,263	2,132	1,984

Capital expenditure (net)	H1 2010	H1 2009	Q2 2010	Q2 2009
Purchase of property, plant and equipment	(227)	(254)	(121)	(142)
- Proceeds from sale of property, plant and equipment	9	5	2	3
= Capital expenditure (net)	(218)	(249)	(119)	(139)

1) Excluding restructuring costs and in-process R&D

Attachment II



Reconciliation of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measure

All figures are in \$ millions

External Revenue	H1 2010	H1 2009	Growth	cc	Q2 2010	Q2 2009	Growth	cc
International product revenue	1,207	1,109	9	5	604	595	1	2
- Internal revenue	(182)	(159)	15		(92)	(85)	8	
= External revenue	1,025	950	8	4	512	510	0	2
North America product revenue	755	704	7		390	360	8	
- Internal revenue	(347)	(308)	12		(180)	(161)	12	
= External revenue	408	396	3		210	199	5	
TOTAL product revenue	1,962	1,813	8	6	994	955	4	5
- Internal revenue	(529)	(467)	13		(272)	(246)	11	
= External revenue	1,433	1,346	6	4	722	709	2	3

Acquisitions (net)	H1 2010	H1 2009	Q2 2010	Q2 2009
Acquisitions and investment and net purchases of intangible assets	(291)	(82)	(207)	(45)
Proceeds from divestitures	8	51	6	50
Acquisitions and investments, net of divestitures	(283)	(31)	(201)	5
Investment, net of repayments	133	(50)	(133)	(50)
Acquisitions, net of divestitures	(150)	(81)	(68)	(45)

cc = constant currency



Strong quarter and fully on track for full-year targets

Very good underlying performance

	Q2 2009	Q2 2010	Growth
Revenue	\$ 2,764 m	\$ 2,946 m	7%
Net income <small>attributable to FMC AG & Co. KGaA</small>	\$ 221 m	\$ 248 m	12%
Earnings per share	\$ 0.74	\$ 0.83	12%

- Strong revenue growth at 7% at constant currency and 6% organic
- Excellent EBIT-margin development
- Resulting in very good net income growth

First Half 2010 – Overview

	H1 2009	H1 2010	Growth
Revenue	\$ 5,323 m	\$ 5,828 m	+9%
Net income <small>attributable to FMC AG & Co. KGaA</small>	\$ 419 m	\$ 459 m	+10%
Earnings per share	\$ 1.41	\$ 1.53	+9%


- Strong revenue growth at 8% at constant currency and 7% organic
- Continued excellent cash flow development



Total revenue increased 7% to \$2,946 m

North America	
Revenue	\$2,027 m
Growth actual	8%
Growth organic	7%

International	
Revenue	\$919 m
Growth cc	5%
Growth organic	3%



Latin America	
Revenue	\$141 m
Growth	15% / 8% cc

Asia-Pacific	
Revenue	\$176 m
Growth	12% / 5% cc

Europe	
Revenue	\$602 m
Growth	-1% / 4% cc

cc = constant currency



Very strong revenue growth globally

First time over 200,000 patients being treated

US\$ millions	Q2 2009	Q2 2010	Growth	cc
North America	1,677	1,817	8%	
International	377	407	8%	9%
Total	2,054	2,224	8%	8%

- Good organic treatment growth of 4.3% globally
- Continued strong revenue per treatment development
- Treating 202,414 patients in 2,599 clinics

cc = constant currency



Very good performance in all key metrics


Q2 2010	Total	North America	International
Organic revenue growth	7%	7%	5%
Same market treatment growth	4.3%	4.2%	4.4%
Revenue per treatment		\$349 ¹⁾	\$159
June 30, 2010			
Number of clinics	2,599	1,795	804
Growth	5%	4%	9%
De novos	45	28	17

1) including Mexico

cc = constant currency



Stable reimbursement environment



Dialysis Services - Global

Q2 2010	Clinics	Patients	Treatments (in millions)
Total	2,599	202,414	15.3
Growth	+ 5%	+ 6%	+ 6%
North America	1,795	135,088	10.2
Growth	+ 4%	+ 5%	+ 6%
International	804	67,326	5.0
Growth	+ 9%	+ 11%	+ 8%
Europe	463	35,277	2.6
Latin America	193	21,761	1.7
Asia-Pacific	148	10,288	0.8



Good product growth in North America

US\$ millions	Q2 2009	Q2 2010	Growth	cc
Total revenue (incl. internal revenue)	955	994	4%	5%
External revenue	709	722	2%	3%
North America	199	210	5%	
International	510	512	0%	2%

cc = constant currency

2nd Quarter 2010 – Profit & Loss






Fresenius Medical Care

US\$ millions	Q2 2009	Q2 2010	Growth
Net revenue	2,764	2,946	7%*
Operating income (EBIT)	418	465	11%
EBIT margin in %	15.1	15.8	
Interest expense, net	76	68	
Income before income tax	342	397	16%
Income tax expense	103	129	
Tax rate	30%	33%	
Non-controlling interest	18	20	
Net income attributable to FMC AG & Co. KGaA	221	248	12%

* 7% growth at constant currency, 6% organic growth






Operating Margin Development





H1 2010 Operating Margin Development





Strong operating cash flow performance



US\$ millions	Q2 2009	Q2 2010	Growth
Operating cash flow ¹⁾	282	294 10% of revenue	4%
Capital expenditures, net ¹⁾	(139)	(119)	
Free cash flow	143	175 6% of revenue	23%
Acquisitions, net of divestitures ^{1) 2)}	(45)	(68)	
Free cash flow, after acquisitions ^{1) 2)}	98	107	

1) A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

2) Does not include a \$133 m cash out for a short-term bank deposit in Q2 2010 and a cash repayment in form of an inter-company loan of \$ 50 m in Q2 2009




Debt/EBITDA ratio ahead of target



* including non-cash charges and in 2007 excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics. A reconciliation to the most directly comparable U.S. GAAP financial measure is provided in the attachment.

ESRD Demonstration Project / FME Cost Model



2010 Guidance and Goal 2013 Strategic Financial Objectives



Fresenius Medical Care

	2010 - Guidance	Goal 13
Revenues	> \$12bn	6-8% Growth*
EBIT Margins	~ 15.6%	10 - 20 bps (incremental increases p.a.)
Interest Expense	< 5.5%	6.0 to 6.5%
Tax Rate	34.5 – 35.5%	35 – 36%
Net Income	\$950 - 980	High single to low double digits
Operating Cash Flow	> 10% of Revenue	> 10% of Revenue
CapEx + Acquisitions	~9% of Revenue	~7% of Revenue

*Constant Currency



Fresenius Medical Care AG & Co. KGaA

Investor Relations

Else-Kröner-Str. 1

61352 Bad Homburg v.d.H.

Ordinary shares

WKN 578 580

ISIN DE0005785802

SEDOL1 5129074 DE

Oliver Maier

Head of Investor Relations & Corporate Communications

Tel.: +49-(0)6172-609-2601

Fax.: +49-(0)6172-609-2301

E-mail: oliver.maier@fmc-ag.com

Gerrit Jost

Tel.: +49-(0)6172-609-5216

Fax.: +49-(0)6172-609-2301

E-mail: gerrit.jost@fmc-ag.com

Terry L. Morris

Tel.: +1-800-948-2538

Fax.: +1-615-345-5605

E-mail: terry.morris@fmc-na.com



Q3 2010 Results

– **Conference Call, November 2, 2010**

For recent updates, please have a look at our website.

www.fmc-ag.com

Calendar

Investor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ...

Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ...

Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data ...

Investor Relations > Our Shares



Fresenius Medical Care

The World's Leading Renal Therapy Company

**Jefferies 2010 Global Specialty Pharma & European Healthcare
Conference**

London, October 6, 2010



Fresenius Medical Care